Cargando…
Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways
BACKGROUND: Cyclooxygenase (COX)-2 is overexpressed in many types of cancers including hepatocellular carcinoma (HCC). Meloxicam, a selective COX-2 inhibitor, has shown potential therapeutic effects against HCC, but the mechanisms accounting for its anti-cancer activities remain unclear. METHODS AND...
Autores principales: | Dong, Xiaofeng, Li, Rui, Xiu, Peng, Dong, Xuesong, Xu, Zongzhen, Zhai, Bo, Liu, Feng, Jiang, Hongchi, Sun, Xueying, Li, Jie, Qiao, Haiquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968044/ https://www.ncbi.nlm.nih.gov/pubmed/24675684 http://dx.doi.org/10.1371/journal.pone.0092864 |
Ejemplares similares
-
Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
por: Zhou, Yinghong, et al.
Publicado: (2020) -
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells
por: Tang, Shuyao, et al.
Publicado: (2016) -
The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival
por: He, Changjun, et al.
Publicado: (2011) -
Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer
por: Zou, Xiaolong, et al.
Publicado: (2008) -
Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam
por: Curtiss, Frederic R.
Publicado: (2006)